ArticleAdvances in therapy2026
Cost-Effectiveness of Earlier Diagnosis of Fibrotic Interstitial Lung Diseases (Fibrotic ILDs) and Earlier Treatment of Its Progressive Form, Progressive Pulmonary Fibrosis (PPF).
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02999178 (A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Impact of time to diagnosis in patients with progressive fibrotic ILD: a systematic review.BMJ open respiratory research · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEarly treatment for progressive pulmonary fibrosis (PPF) improves outcomes. However, diagnosis of fibrotic-interstitial lung diseases (fibrotic ILDs) and detection of potentially emergent PPF are delayed by 9-12 months on average. New ILD diagnostic and PPF monitoring strategies are being investigated to enable early treatment and improve patient outcomes.
methodsA time-to-event cost-effectiveness model for reducing delays in ILD diagnosis and PPF detection was developed. Model inputs were obtained from ILD expert clinicians, the literature, and statistical progression equations derived from the INBUILD trial. The study investigated discounted health economic outcomes of early diagnosis of ILD and detection of PPF in eight European countries (Belgium, Denmark, Finland, Greece, Norway, The Netherlands, Portugal, and Sweden).
resultsThe study highlights substantial benefits from reducing the time to diagnose fibrotic ILD and identifying PPF across various ILD subtypes. Clinical advantages arise from any reduction in diagnostic delays, primarily by delaying the onset of PPF and facilitating earlier nintedanib treatment. The model indicates that earlier diagnosis results in quality-adjusted life-year (QALY) gains across all countries, with improvements ranging from 0.061 to 0.084 in the base case. Furthermore, all tested scenarios confirm the cost-effectiveness of early diagnosis of fibrotic ILD and of PPF detection across all studied countries.
conclusionEarly diagnosis of ILD and detection of PPF yield cost-effective clinical benefits, supporting the adoption of approaches to speed up ILD diagnosis and PPF detection.
trial registrationClinicalTrials.gov identifier, NCT02999178.
Indexed as
Identifiers
42084658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.